ProKidney Corp. (NASDAQ:PROK – Get Free Report) insider Darin J. Weber sold 16,412 shares of the stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $2.50, for a total value of $41,030.00. Following the completion of the sale, the insider now owns 103,480 shares in the company, valued at $258,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
ProKidney Price Performance
Shares of NASDAQ PROK opened at $2.46 on Friday. The business has a 50-day moving average of $2.28 and a two-hundred day moving average of $2.38. The company has a market capitalization of $564.19 million, a price-to-earnings ratio of -4.32 and a beta of 1.10. ProKidney Corp. has a 1 year low of $1.12 and a 1 year high of $4.98.
ProKidney (NASDAQ:PROK – Get Free Report) last posted its earnings results on Friday, August 9th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. As a group, equities research analysts expect that ProKidney Corp. will post -0.44 earnings per share for the current year.
Analyst Ratings Changes
Read Our Latest Stock Report on ProKidney
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp lifted its position in ProKidney by 44.6% in the second quarter. Bank of New York Mellon Corp now owns 179,236 shares of the company’s stock valued at $441,000 after acquiring an additional 55,266 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of ProKidney by 8.8% in the 2nd quarter. Rhumbline Advisers now owns 76,190 shares of the company’s stock valued at $187,000 after purchasing an additional 6,181 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of ProKidney in the 2nd quarter valued at about $124,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of ProKidney in the 2nd quarter valued at about $106,000. Finally, The Manufacturers Life Insurance Company purchased a new position in ProKidney during the 2nd quarter worth approximately $60,000. 51.59% of the stock is owned by hedge funds and other institutional investors.
ProKidney Company Profile
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
Read More
- Five stocks we like better than ProKidney
- The Basics of Support and Resistance
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- The Most Important Warren Buffett Stock for Investors: His Own
- MarketBeat Week in Review – 9/16 – 9/20
- The 3 Best Retail Stocks to Shop for in August
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.